Last updated: April 24, 2026
Bortezomib supply chains typically split into (1) drug substance (API) and (2) finished sterile drug product (vials for IV/SC dosing). The supplier landscape is dominated by originator and authorized generic manufacturers for the drug product, while API is often sourced from specialized chemical producers with qualification by formulators and distributors.
What supplier categories matter for bortezomib procurement?
Bortezomib procurement generally breaks into two practical paths:
- Drug product suppliers (marketed vials): companies that manufacture and release the sterile lyophilized powder or solution in final pack form (strengths and labeling aligned to local markets).
- API (bortezomib) suppliers: companies that produce bortezomib as a chemical intermediate for formulation by sterile manufacturing sites or contract manufacturers.
In practice, companies buying “bortezomib” should treat these as different supply qualification workstreams because sterile fill-finish and GMP release often drive lead times more than API availability.
Which drug product suppliers supply bortezomib vials globally?
Bortezomib is sold under multiple brand and authorized generic names. Common global originator and downstream brand ownership patterns include:
- Originator: bortezomib is marketed under VELCADE.
- Authorized generic and local brands: multiple manufacturers distribute bortezomib in their own labeling across regions where they have regulatory approvals.
Where this matters for sourcing: drug product suppliers determine container closure system, excipients, lyophilization/process controls, and distribution packaging standards. For hospitals and distributors, the vendor is usually the marketer/manufacturer of the specific labeled product line rather than the API producer.
Which companies are associated with VELCADE (bortezomib) manufacturing and distribution?
VELCADE is the best-anchored reference point for supplier mapping because it links bortezomib to a branded product supply chain.
- Janssen is associated with VELCADE in the United States (brand owner/marketer) and with global commercialization through the Janssen network. VELCADE labeling ties bortezomib to Janssen’s commercial infrastructure. (See FDA label entry for VELCADE.) [1]
Which API suppliers are linked to bortezomib drug substance manufacturing?
API sourcing is typically done through chemical manufacturers listed in:
- public procurement and catalog sources (commercial listings),
- DMF-linked or dossier-linked filings in regulatory workflows, and
- qualification records held by finished-dose manufacturers.
However, without market-specific dossier identifiers and without explicit supplier-to-DMF mapping in the public record provided here, a complete, accurate API vendor list cannot be produced in a way that meets procurement-grade verification standards.
How do you validate a bortezomib supplier for compliance and supply continuity?
For bortezomib, validation should cover both chemical quality (API) and sterile drug product controls. A practical qualification checklist for procurement teams is:
Drug product supplier qualification (sterile vials)
- GMP status and inspection history for sterile fill-finish and drug product release.
- Evidence of batch traceability to the specific lot distribution in the market channel.
- Confirmation that the supplier’s bortezomib strength and presentation match the intended use (IV vs SC protocols depend on product-specific dosing instructions).
- Supply chain controls for lyophilized products (cold chain is product- and label-dependent, but moisture control and storage conditions are critical).
API supplier qualification
- DMF/dossier linkage in the finished-dose filing pathway (or equivalent regulatory support).
- Impurity profile controls and method validation package availability.
- Consistent particle size and polymorphic control if applicable to the API process.
- Change notification discipline (process changes can impact impurity formation).
What are the main bortezomib dosing formats and why they affect supplier selection?
Bortezomib is commonly supplied as sterile vials for IV administration and as subcutaneous (SC) dosing under clinical protocols. Supplier selection changes depending on:
- availability of a specific labeled formulation for the intended route, and
- compatibility with institutional reconstitution and administration workflows.
The FDA label for VELCADE provides dose/administration context for route use in approved regimens. [1]
Supplier evidence anchored to authoritative labeling
For procurement decisions, FDA labeling is a reliable anchor for product identity and marketed supply chain references:
- VELCADE (bortezomib) is documented in the FDA labeling record for bortezomib. [1]
This anchor supports brand ownership and product-level sourcing, not necessarily the underlying API manufacturer.
What is the most actionable way to structure a supplier shortlist?
A procurement shortlist should be built as two lists:
1) Finished-dose (drug product) suppliers for the labeled strength and presentation required in the target market.
2) API suppliers only where your organization controls formulation or where contract formulation requires explicit API procurement.
The shortlist should prioritize:
- suppliers with direct market approval in the destination country,
- stable release performance (lot availability continuity),
- and documented GMP compliance.
Where can you confirm bortezomib supplier and product identity quickly?
The fastest public verification path for product identity is:
- regulatory product labeling repositories (for drug product),
- brand owner websites and regulatory label identifiers,
- and clinical labeling references that map “what product” is being used (not “who made the API”).
For bortezomib in the US context, the FDA VELCADE labeling record is the key public anchor. [1]
Key tables for decision-making
Table 1. Supplier categories and what they control
| Procurement object |
Typical supplier type |
What it controls |
Main risk |
| Bortezomib vials |
Drug product manufacturer/marketer |
Sterile manufacturing, formulation, labeling, lot release |
Sterility and supply availability |
| Bortezomib API |
Chemical API manufacturer |
Chemical quality, impurity profile, consistency |
Regulatory support and process change risk |
Table 2. Anchor source for product identity
| Item |
Authoritative source |
What you get |
| VELCADE (bortezomib) product |
FDA labeling record |
Marketed product identity, dosing and label-specific information tied to the brand supply chain |
Key Takeaways
- Bortezomib supply should be managed by drug product and API procurement tracks because qualification drivers differ sharply between sterile release and chemical quality controls.
- VELCADE is the best public anchor for bortezomib product identity and brand supply chain references in the US via the FDA label. [1]
- A complete API supplier list cannot be produced to procurement-grade verification standards from the provided public anchor alone; product-level supplier mapping should be used first, then API supplier qualification can be aligned to formulation dossiers and DMF-linked documentation.
FAQs
1) Is bortezomib procurement primarily a drug product problem or an API problem?
For most healthcare and distribution buyers, it is primarily a drug product problem because lot release, sterile manufacturing, and labeled presentation drive availability.
2) What is the most reliable public reference for bortezomib product identity in the US?
The FDA label for VELCADE (bortezomib) is the most direct anchor for product identity. [1]
3) Do drug product suppliers always control the API?
Not necessarily. Many drug product manufacturers formulate using qualified external APIs; API source and DMF linkage are separate qualification threads.
4) Why do IV vs SC protocols matter for supplier selection?
Because dosing instructions and approved administration context attach to the specific labeled product, affecting which vials are appropriate for institutional workflows. [1]
5) What should be prioritized when building a supplier shortlist?
Prioritize market-approved labeled drug product availability first, then align API qualification to the formulation and regulatory dossier pathway.
References
[1] U.S. Food and Drug Administration. (n.d.). VELCADE (bortezomib) prescribing information / label. FDA. https://www.accessdata.fda.gov/
